In lung cancer, it promotes tumour progression through the PI3K/AKT pathway, resulting in increased expression of p21; silencing KIF4A leads to upregulation of p21 and heightened sensitivity to doxorubicin [38]. Here, KIF4A is linked to neoplasm.